Hematologic Oncology | Specialty

Latest News & Insight: December 19, 2014

December 19th 2014

Clonal Hematopoiesis in Normal Individuals Might Represent a New Way to Approach Blood Cancer Risk and Diagnosis

December 19th 2014

Cancers arise from multiple acquired mutations that presumably occur over many years, as shown in a number of models, particularly in colon cancer.

Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin Combo

December 16th 2014

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Duvelisib Produces Responses in Indolent Non-Hodgkin Lymphoma

December 16th 2014

Duvelisib (IPI-145), an inhibitor of PI3K-δ and PI3K-γ signaling, had a favorable risk:benefit profile in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) in a phase I study, reported Ian Flinn, MD, PhD

Tyrosine Kinase Inhibitor Shows Promise in AML

December 15th 2014

Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.

Two Experts Discuss JAK Inhibition in Polycythemia Vera

December 11th 2014

2014 ASH Annual Meeting

December 11th 2014

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

December 11th 2014

BCL-2 Inhibitor Venetoclax Demonstrates Activity in Pretreated AML

December 9th 2014

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Ibrutinib Combination Produces High Response Rate in Relapsed/Refractory MCL

December 9th 2014

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

Stem Cell Transplant Feasible, Highly Effective for HIV-Associated Lymphoma

December 8th 2014

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL

December 8th 2014

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.

IDH2-Targeting Agent Has Positive Early Results in AML

December 8th 2014

The novel drug AG-221 generated durable remissions in patients with AML by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy.

CAR T-Cell Therapy Elicits High Response Rate in Pediatric ALL

December 7th 2014

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

December 7th 2014

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML

December 7th 2014

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

Blinatumomab Leads to High MRD Response in B-Precursor ALL

December 7th 2014

At least 80% of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with the CD19-directed antibody blinatumomab.

Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells

December 6th 2014

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

FDA Approves Ruxolitinib for Polycythemia Vera

December 4th 2014

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea